Previous 10 | Next 10 |
SAN DIEGO , Feb. 6, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its second quarter ended December 31, 2019 . "We're off to a good start in calendar year 2020....
We've posted a 4-page quarterly letter. Speed Read: We briefly review the building momentum unwind lurking in ETFs, the terrible governance shifts that have been occurring, and the directly opposite approach to governance we are taking at our largest position; The intrinsic value...
Shares of MEI Pharma (MEIP) have risen by 23% since my November 2017 article called the stock a prime turnaround candidate due to multiple material catalysts expected for its oncology-focused pipeline. On the other hand, shares have fallen by 40% since my post ASCO update in 2018 in which ...
Women and cats will do as they please, and men and dogs should relax and get used to the idea. " - Robert A. Heinlein I have had a few questions come up from followers around a $2 biotech stock called MEI Pharma ( MEIP ) in recent weeks. Given it has been a long time since I glance at thi...
It’s A Short Week But These Penny Stocks Could Be On Watch Lists Starting Tomorrow The holidays are always an interesting time for the stock market, in general. However, when it comes to penny stocks , there are even more things to be aware of. First, the typical liquidity in the marke...
SAN DIEGO , Dec. 19, 2019 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it has closed the underwritten public offering of 32,343,750 shares of its common stock, including 4,218,...
Gainers: Kaixin Auto (NASDAQ: KXIN ) +32% . More news on: Kaixin Auto Holdings, NantKwest, Inc., Renewable Energy Group, Inc., Stocks on the move, Read more ...
Proteostasis Therapeutics (NASDAQ: PTI ) -37% on mixed results in mid-stage CF study. More news on: Proteostasis Therapeutics, Inc., MEI Pharma, Inc., VistaGen Therapeutics, Inc., Stocks on the move, Read more ...
MEI Pharma (NASDAQ: MEIP ) has priced its public offering of 28,125,000 common shares at $1.60 per share for total gross proceeds of ~$45M. More news on: MEI Pharma, Inc., Healthcare stocks news, Stocks on the move, Read more ...
SAN DIEGO , Dec. 17, 2019 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it has priced the underwritten public offering of 28,125,000 shares of its common stock at $1.60 per sh...
News, Short Squeeze, Breakout and More Instantly...
Company Commences a Cash Preservation Plan Including a Reduction in Force MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company’s strategic alternatives, including ...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...